Business
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2026, and provided a corporate update.
About this update from Armata Pharmaceuticals, Inc.
[{"type":"text","content":"Entered into secured credit agreement with Innoviva for $25 million maturing in 2029","length":84,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its first quarter ended March 31, 2026, and provided a corporate update.","length":471,"tagName":"p"},{"type":"image","alt":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"Armata Pharmaceuticals Logo (PRNewsfoto/Armata Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":233,"url":"https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bvnlEtALuiGK.3Dxno4EVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQxMTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d","width":400,"height":233},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/lux6UmLJ.MZbCUVv_XNajg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTM3MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7c5ae7fba5bf4523a1183526f430008d","width":400,"height":233}},"href":"https://mma.prnewswire.com/media/884786/Armata_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""Our top priority in 2026 is advancing Armata's lead Staphylococcus aureus ("S. aureus") therapeutic phage candidate, AP-SA02, into a Phase 3 superiority study in complicated S. aureus bacteremia ("SAB")," said Dr. Deborah Birx, Chief Executive Officer of Armata. "We are focused on initiating a rigorously designed and operationally efficient study designed to support a future Biologics License Application ("BLA") submission and potential registration. If successful, AP-SA02 has the potential to offer an important new treatment option for patients facing this serious and often life-threatening infection. We believe this program will establish a foundation for expanding our phage platfo...